Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth - GBI Research Reports

Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth

Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth - GBI Research Reports
Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth
Published Sep 17, 2011
151 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth. The report provides in-depth analysis of drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes -
- Annualized market data for the blood disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including anemia, thrombosis, neutropenia, hemophilia A, hemophilia B, hemophilia C, von Willebrands disease and Alexander disease.
- Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the blood disorders market, including market size, annual cost of treatment and treatment usage pattern.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Bristol-Myers Squibb, Sanofi-Aventis, Baxter and Centocor Ortho Biotech Inc.
- Key M&A activities, licensing agreements, that have taken place from 2004 to 2011 in the global blood disorders market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

  
Source:
Document ID
GBIHC129MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents48
  List of Tables73
  List of Figures102
Blood Disorders Therapeutics Market to 2017 - Introduction121
  GBI Research Report Guidance121
Blood Disorders Therpauetics Market to 2017 - Market Overview1310
  Introduction131
    Revenue132
      Branded Vs Generics151
    Annual Cost of Treatment161
    Treatment Usage Patterns171
      Diseased Population181
      Treatment Seeking Population181
      Diagnosed Population191
      Prescription Population191
  Market Drivers191
    Steady Increase in the Prevalence Population, Particularly in the Top Five Countries of Europe191
    Rapid Uptake of Recombinant Products and Biologics due to Better Efficacy, Safety and Convenient Dosing191
    Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable201
    Increase in Blood Disorders Causing Conditions such as Cancer and Cardiovascular Events201
  Market Restraints211
    Low Diagnosis Rate as the Contemporary Diagnostic Tools Unable to Diagnose Most Severe Forms of Blood Disorders211
    Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market211
    Clearance of the Regulatory Pathway in the US Will Open up the World s Largest Pharmaceutical Market to Biosimilar Players211
    Sluggish Growth in the Annual Cost of Treatment for Blood Disorders is Expected to Drive Down the Growth Rate221
Blood Disorders Therapeutics Market to 2017 - Geographical Landscape2318
  Geographical Break-up232
  The US251
    Revenue251
    Annual Cost of Treatment261
    Treatment Usage Patterns271
      Diseased Population281
      Treatment Seeking Population281
      Diagnosed Population291
      Prescription Population291
  Top Five Countries of Europe301
    Revenue301
    Country Segmentation312
    Annual Cost of Treatment331
    Treatment Usage Patterns341
      Diseased Population351
      Treatment Seeking Population351
      Diagnosed Population361
      Prescription Population361
  Japan371
    Revenue371
    Annual Cost of Treatment381
    Treatment Usage Patterns391
      Diseased Population401
      Treatment Seeking Population401
      Diagnosed Population401
      Prescription Population401
Blood Disorders Therapeutics Market to 2017 - Therapeutic Landscape4169
  Thrombosis Market411
    Introduction411
    Revenue412
      Geographic Segmentation431
      Branded Vs Generics441
    Annual Cost of Treatment451
    Treatment Flow Algorithm461
    Treatment Usage Patterns471
      Diseased Population481
      Treatment Seeking Population481
      Diagnosed Population491
      Prescription Population491
  Anemia Market491
    Introduction491
    Revenue501
      Geographic Segmentation512
      Branded Vs Generics531
    Annual Cost of Treatment541
    Treatment Flow Algorithm551
    Treatment Usage Patterns561
      Diseased Population571
      Treatment Seeking Population571
      Diagnosed Population581
      Prescription Population581
  Neutropenia Market591
    Introduction591
    Revenue601
      Geographic Segmentation611
      Branded Vs Generics621
    Annual Cost of Treatment631
    Treatment Flow Algorithm641
    Treatment Usage Patterns651
      Diseased Population661
      Treatment Seeking Population661
      Diagnosed Population661
      Prescription Population671
  Hemophilia A Market671
    Introduction671
    Revenue682
      Geographic Segmentation701
      Branded Vs Generics711
    Annual Cost of Treatment721
    Treatment Flow Algorithm731
    Treatment Usage Patterns741
      Diseased Population751
      Treatment Seeking Population751
      Diagnosed Population761
      Prescription Population761
  Hemophilia B Market761
    Introduction761
    Revenue772
      Geographic Segmentation791
      Branded Vs Generics801
    Annual Cost of Treatment811
    Treatment Flow Algorithm821
    Treatment Usage Patterns831
      Diseased Population841
      Treatment Seeking Population841
      Diagnosed Population851
      Prescription Population851
  Hemophilia C Market851
    Introduction851
    Revenue861
      Geographic Segmentation871
      Branded Vs Generics881
    Annual Cost of Treatment891
    Treatment Flow Algorithm901
    Treatment Usage Patterns911
      Diseased Population921
      Treatment Seeking Population921
      Diagnosed Population921
      Prescription Population921
  von Willebrand s Disease (vWD) Market931
    Introduction931
    Revenue941
      Geographic Segmentation951
      Branded Vs Generics961
    Annual Cost of Treatment971
    Treatment Flow Algorithm981
    Treatment Usage Patterns991
      Diseased Population1001
      Treatment Seeking Population1001
      Diagnosed Population1001
      Prescription Population1001
  Alexander s Disease (Factor VII Deficiency) Market1011
    Introduction1011
    Revenue1012
      Geographic Segmentation1031
      Branded Vs Generics1041
    Annual Cost of Treatment1051
    Treatment Flow Algorithm1061
    Treatment Usage Patterns1071
      Diseased Population1081
      Treatment Seeking Population1081
      Diagnosed Population1081
      Prescription Population1091
Blood Disorders Therapeutics Market to 2017 - Pipeline Analysis11016
  Introduction1101
    Research and Development Pipeline Thrombosis1112
    Research and Development Pipeline Anemia1132
    Research and Development Pipeline Neutropenia1152
    Research and Development Pipeline Hemophilia1173
    Research and Development Pipeline von Willebrand Disease (vWD)1201
    Research and Development Pipeline Alexander s Disease1211
  Profiles of Promisisng Molecules in the Blood Disorders Market1211
    Brilinta/Brilique1211
      Introduction1211
      Mechanism of Action1211
      Clinical Trial Management1211
    R7441221
      Introduction1221
      Mechanism of Action1221
      Clinical Trial Management1221
    VGX-32001231
      Introduction1231
      Mechanism of Action1231
      Clinical Trial Management1231
    Nupen1241
      Introduction1241
      Mechanism of Action1241
      Clinical Trial Management1241
    NecLip-pdFVIII1251
      Introduction1251
      Mechanism of Action1251
      Clinical Trial Management1251
Blood Disorders Therapeutics Market to 2017 - Competitive Landscape1269
  Market Share Analysis: Blood Disorders1261
  Competitive Profiling1261
    Amgen1261
      Company Overview1261
      Product Portfolio1262
      SWOT Analysis1281
    Bristol-Myers Squibb1281
      Company Overview1281
      Product Portfolio1281
      SWOT Analysis1291
    Sanofi1301
      Company Overview1301
      Product Portfolio1301
      SWOT Analysis1311
    Baxter International Inc.1321
      Company Overview1321
      Product Portfolio1321
      SWOT Analysis1331
    Centocor Ortho Biotech Inc.1331
      Company Overview1331
      Product Portfolio1341
      SWOT Analysis1341
Blood Disorders Therapeutics Market to 2017 - Strategic Consolidations1359
  M&A Deals1351
  Deals by Indication1351
  Deals by Geography1361
  Deals by Value1371
  Major M&A Deals1381
    GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 20091391
    Biovitrum AB Acquired Swedish Orphan International AB in November 20091391
    Pfizer Acquired Wyeth in January 20091391
    Baxter International to Acquire Hemophilia-Related Assets from Archemix in November 20101391
    Paul Capital Healthcare Acquires Rights to Xyntha from Dyax in April 20101401
    Baxter Healthcare Acquires Rights to AV513 from Avigen in December 20081401
    Bayer HealthCare Acquires MAXY-VII from Maxygen in July 20081401
    Accredo Health Acquires Hemophilia Resources of America in July 20041401
    CSL Acquires Aventis Behring from Aventis in March 20041401
  Licensing Agreements1411
    Deals by Indication1411
    Deals by Geography1421
    Deals by Value ($)1431
Blood Disorders Therapeutics Market to 2017 - Appendix1448
  Market Definitions1441
  Abbreviations1441
  Research Methodology1452
    Coverage1451
    Secondary Research1451
    Primary Research1461
  Therapeutic Landscape1463
    Epidemiology-based Forecasting1471
    Market Size by Geography1481
  Geographical Landscape1491
  Pipeline Analysis1491
  Competitive Landscape1491
    Expert Panel Validation1491
  Contact Us1491
  Disclaimer1501
  Sources1502

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Blood-Disorders-Therapeutics-Market-to-2017-Patent-Expiries-of-Lovenox-Plavix-Procrit-Epogen-Aranesp-and-Neulasta-Will-Slow-Down-Growth-2115-260>
  
APA:
GBI Research Reports. (2011). Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Blood-Disorders-Therapeutics-Market-to-2017-Patent-Expiries-of-Lovenox-Plavix-Procrit-Epogen-Aranesp-and-Neulasta-Will-Slow-Down-Growth-2115-260>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.